Trial Profile
A randomized, double-blind, parallel group placebo-controlled study of the safety and reduction of signs and symptoms during treatment with tocilizumab (TCZ) [Actemra; Roche] versus placebo in patients with ankylosing spondylitis who have had an inadequate response to previous TNF [tumour necrosis factor] antagonist therapy
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 03 Aug 2022
Price :
$35
*
At a glance
- Drugs Tocilizumab (Primary)
- Indications Ankylosing spondylitis
- Focus Therapeutic Use
- Acronyms BUILDER-2
- Sponsors Roche
- 31 Jul 2022 This trial has been completed in Spain (End Date: 28 Dec 2011), according to European Clinical Trials Database record.
- 13 Jun 2013 Results published in the Annals of the Rheumatic Diseases.
- 08 Apr 2013 New source identified and integrated (Clinical Trials Registry - India: CTRI2011-04-001692).